Abstract
The ability of lentiviral vectors to transduce and stably integrate their genomes into non-dividing cells was the major reason for the development of the HIV-1 based vector gene delivery system. The first VSVG pseudotyped lentiviral vectors fulfilled these expectations by ferrying large genetic payloads to nondividing cells in vitro and in vivo. Here we discuss advances in HIV-1 vector systems which lead to improvement in biosafety, transduction efficiency, longevity and regulation of transgene expression, and vector production. The successful use of the advanced HIV-1 based vector system opened new avenues in establishing transgenic animal models for basic research. Additionally, we describe accomplishments using HIV-1 based vectors to correct pathological courses of incurable diseases in preclinical animal models including Parkinsons disease and β-thalassemia.
Keywords: lentiviral vector, gene therapy, animal model, pseudotype, tetracycline
Current HIV Research
Title: HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go
Volume: 1 Issue: 4
Author(s): Adam S. Cockrell and Tal Kafri
Affiliation:
Keywords: lentiviral vector, gene therapy, animal model, pseudotype, tetracycline
Abstract: The ability of lentiviral vectors to transduce and stably integrate their genomes into non-dividing cells was the major reason for the development of the HIV-1 based vector gene delivery system. The first VSVG pseudotyped lentiviral vectors fulfilled these expectations by ferrying large genetic payloads to nondividing cells in vitro and in vivo. Here we discuss advances in HIV-1 vector systems which lead to improvement in biosafety, transduction efficiency, longevity and regulation of transgene expression, and vector production. The successful use of the advanced HIV-1 based vector system opened new avenues in establishing transgenic animal models for basic research. Additionally, we describe accomplishments using HIV-1 based vectors to correct pathological courses of incurable diseases in preclinical animal models including Parkinsons disease and β-thalassemia.
Export Options
About this article
Cite this article as:
Cockrell S. Adam and Kafri Tal, HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go, Current HIV Research 2003; 1 (4) . https://dx.doi.org/10.2174/1570162033485104
DOI https://dx.doi.org/10.2174/1570162033485104 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lanthionine Synthetase Component C-Like Protein 2: A New Drug Target for Inflammatory Diseases and Diabetes
Current Drug Targets Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Virotherapy as An Approach Against Cancer Stem Cells
Current Gene Therapy Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Current Pharmaceutical Design Accuracy of a Topical PET/CT Scanner on SUV Measurements of Small Volumes SUV
Current Medical Imaging Molecular Dynamics as a Tool in Rational Drug Design: Current Status and Some Major Applications
Current Computer-Aided Drug Design Prediction of Cancer Rescue p53 Mutants In Silico Using Naïve Bayes Learning Methodology
Protein & Peptide Letters Compounds from Wild Mushrooms with Antitumor Potential
Anti-Cancer Agents in Medicinal Chemistry Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Flavonoids and other Non-alkaloidal Constituents of Genus Erythrina: Phytochemical Review
Combinatorial Chemistry & High Throughput Screening Biotechnological Production of Taxol and Related Taxoids: Current State and Prospects
Anti-Cancer Agents in Medicinal Chemistry C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Current Pharmaceutical Design New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Chemomodulating Effects of Flavonoids in Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry A Novel Highly Selective Cannabinoid CB2 Agonist Reduces in vitro Growth and TGF-beta Release of Human Glial Cell Tumors
Central Nervous System Agents in Medicinal Chemistry Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors
Current Medicinal Chemistry 1,2,4-Triazine Chemistry Part III: Synthetic Strategies to Functionalized Bridgehead Nitrogen Heteroannulated 1,2,4-Triazine Systems and their Regiospecific and Pharmacological Properties
Current Organic Synthesis Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry